- 1
- 2
Arecor Ltd
Arecor has a proprietary and patented technology platform for improving the stability of a range of therapeutic proteins including vaccines, monoclonal antibodies, peptides, blood factors and fusion proteins
Dr Sarah Howell
Chief Operations OfficerDomainex
Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates
Dr Eddy Littler
Chief Executive OfficerDr Keith Powell
ChairmanHaemostatix
Haemostatix has developed a new class of peptide-based haemostat for the treatment of bleeding. The technology is based on a peptide that binds to the blood protein fibrinogen, inducing the rapid and targeted formation of clots.
Dr Ben Nichols
Chief Executive OfficerIntegrated Magnetic Systems Ltd
IMS offers magnetic antibodies and adaptor proteins to the life science community (research and bioprocessing) while further developing the technology platform for licensing and partnering opportunities in medicine (diagnostics and therapeutics).
Dr Eddie Blair
Chief Executive OfficerInternational Bioscience Managers
IBML, through its associate companies, OctaPhillip Bioscience Managers Ltd and Union MedTech PLC, specialises in investment in life science and medical technology companies.
Mr Jeremy Curnock Cook
Managing DirectorKymab
Kymab is a biopharmaceutical company engaged in the discovery and development of human monoclonal antibody therapeutics.
Dr Tom Shepherd
Chief Business OfficerPolyTherics Ltd
PolyTherics is a biotechnology company that offers a comprehensive range of site-specific conjugation technologies and polymer-based technologies which are being applied to the development and enhancement of biologicals and other therapeutic entities.
Dr John Burt
Chief Executive OfficerDr Jennifer Filbey
US consultantProsonix Ltd
Prosonix is a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines enabled by its state-of-the-art particle engineering technology.
Mr David Hipkiss
Chief Executive OfficerMr Andy Bush
Chief Operating OfficerReneuron
ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.